Sarcopenia among treated cancer patients before and after neoadjuvant chemotherapy: a systematic review and meta ‐analysis of high-quality studies

ConclusionThe risk of muscle reduction significantly increases in cancer patients after neoadjuvant chemotherapy and digestive system cancers tend to have a higher risk of developing sarcopenia post-treatment compared to non-digestive system cancers.
Source: Clinical and Translational Oncology - Category: Cancer & Oncology Source Type: research